2Suppliers
1Customers
3Debt Items
12Related Chains

Precigen, Inc. Suppliers

TickerNameConfidenceEvidence
CLLS Cellectis S.A. 72% ions will be subject to FCPA, which prohibits, among other things, United States companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, …
CLLS Cellectis S.A. 72% Reciprocal relationship from CLLS graph: Reciprocal relationship from PGEN graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from PGEN graph: Reciprocal relationship from CLLS g…

Precigen, Inc. Customers

TickerNameConfidenceEvidence
EXEMPLAR EXEMPLAR 92% Service revenues, which were all generated by Exemplar.

Precigen, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
PGEN-DEBT-11754 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.
PGEN-DEBT Debt stack $98.2M 90% Market cache reports total debt of $98.2M.
PGEN-DEBT-11753 Warrants outstanding: 190060000 90% xbrl warrant detail from xbrl 2025-12-31.

Precigen, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Precigen, Inc..

Precigen, Inc. Ownership

HolderNameConfidenceEvidence
PGEN-OWNER-PATIENT-CAPITAL-MANAGEMENT-LLC Patient Capital Management, LLC 90% 13F overlay lists Patient Capital Management, LLC as top holder; 205 tracked holders.

Precigen, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CLLS Cellectis S.A. 100.00 1 ['supplier']
DTIL Precision BioSciences, Inc. 50.00 2
AZN AstraZeneca PLC 50.00 2
ALLO Allogene Therapeutics, Inc. 50.00 2
BMY Bristol-Myers Squibb Company 50.00 2
BMYMP Bristol-Myers Squibb Co 50.00 2
TKPHF Takeda Pharmaceutical Company Limited 50.00 2
TMO Thermo Fisher Scientific Inc. 50.00 2
IOVA Iovance Biotherapeutics, Inc. 50.00 2
LYEL Lyell Immunopharma, Inc. 50.00 2
AUTL Autolus Therapeutics plc 50.00 2
NTLA Intellia Therapeutics, Inc. 50.00 2